To direct the Administrator of the Federal Aviation Administration to include medications and medical equipment for the emergency treatment of known or suspected opioid overdose in aircraft emergency medical kits, and for other purposes.

Bill 118 hr 3616, also known as the Opioid Overdose Prevention in Aviation Act, aims to address the growing opioid crisis by requiring the Federal Aviation Administration (FAA) to include medications and medical equipment for the emergency treatment of known or suspected opioid overdoses in aircraft emergency medical kits.

The bill mandates that the FAA update their regulations to ensure that all commercial aircraft are equipped with naloxone, a medication used to rapidly reverse the effects of opioid overdose, as well as other necessary medical supplies for treating opioid overdoses. This requirement is crucial in ensuring that passengers and crew members have access to life-saving treatment in the event of an opioid-related emergency while in the air.

In addition to requiring the inclusion of naloxone and other medical supplies in aircraft emergency medical kits, the bill also directs the FAA to provide training to flight attendants and other relevant personnel on how to administer naloxone and respond to opioid overdoses effectively. This training is essential in ensuring that airline staff are prepared to handle opioid-related emergencies and provide timely and appropriate care to passengers in need. Overall, the Opioid Overdose Prevention in Aviation Act is a crucial step towards addressing the opioid crisis and ensuring the safety and well-being of airline passengers and crew members. By requiring the inclusion of naloxone and other medical supplies in aircraft emergency medical kits, as well as providing training to airline staff, this bill has the potential to save lives and prevent tragic outcomes related to opioid overdoses in the aviation industry.